Hypothermia and advanced neuromonitoring

Abstract

Therapeutic hypothermia (TH) improves short-term neurologic outcome and reduces mortality after cardiac arrest (CA) [1]. Neuroprotective mechanisms comprise reduced cerebral metabolic demand [2,3], decreased excitotoxicity [4-7], cell membrane stabilization [8,9], inhibition of spreading depolarizations [10] and cytokine release [11], and preservation of cerebral autoregulation. This concept of neuroprotection led to clinical trials using TH for the prevention of secondary brain injury in patients with traumatic brain injury, subarachnoid hemorrhage (SAH) and ischemic stroke; however, they failed to show any benefit in clinical outcomes [12-15]. This may reflect our lack of understanding of the exact pathophysiologic processes induced by TH and the potential harm through hypothermia and rewarming injury [16]. Advanced neuromonitoring techniques allow online measurement of brain metabolism, cerebral autoregulation, brain tissue oxygenation, and cerebral blood flow (CBF) and provide information about brain function, energy supply and demand [17-19]. Here we will summarize current knowledge about the effects of TH on brain homeostasis after acute brain injury using advanced neuromonitoring techniques and call for more observational trials investigating pathophysiologic mechanisms during TH and rewarming to maximize the benefits of this emerging therapeutic modality. TH effectively decreases intracranial pressure (ICP) by up to 10 mmHg [12,20-22], whereby mild hypothermia (35degreeC) seems to be as effective as 33degreeC [21,23]. Mechanisms include the reduction in metabolic demand and the inhibitory effect on inflammation and free radical production stabilizing the blood-brain barrier and decreasing vasogenic edema [20,24-26]. Cerebral microdialysis allows bedside monitoring of cerebral metabolic changes from the extracellular fluid of the brain [27]. Decreased energy supply, increased demand or mitochondrial dysfunction may result in brain metabolic distress and/or brain hypoglycemia (brain glucose 2 probes [39,40]. Therapeutic hypothermia below 35degreeC may impair brain tissue oxygenation through a left-shift of the oxygen dissociation curve, therefore enhancing the affinity of oxygen to hemoglobin, or by decreasing delivery of oxygen to the brain [21,41]. Jugular bulb oxygen saturation (jSvO2) is a global measurement of brain oxygen extraction and is increased during mild TH [31,41], reflecting a reduction in cerebral metabolic rate of oxygen. Shivering is frequently observed during TH and may abolish the neuroprotective effect of temperature modulation through increase in metabolic demand and systemic and cerebral energy consumption [42]. A shivering-associated reduction in PbtO2 seems to correlate with the intensity of therapeutic cooling and potentially increases the risk of brain hypoxia [43]. These results imply that the neuroprotective effect of TH may be most beneficial at a temperature not lower than 35degreeC and shivering should be assessed at the bedside and effectively treated by pharmacological and nonpharmacological means [42]. It is important to note that CO2 reactivity may be preserved during TH [44]. Therapeutic hyperventilation as TH is used as rescue therapy to decrease raised ICP and unintentional hypocapnia is also commonly observed in patients with acute brain injury [45], which increases the risk of brain tissue hypoxia [38]. Monitoring of brain tissue oxygen or jugular venous oxygen saturation (jSvO2) is recommended for patients with acute traumatic brain injury, where therapeutic hyperventilation is used [46] and is important especially during TH. Preserved cerebral autoregulation seems not to be disturbed during TH and early induction of hypothermia after SAH led to faster restoration of cerebrovascular reactivity in vivo [6,47,48]. The rewarming has been considered as the vulnerable phase following TH [42,49,50]. Rapid rewarming and timing in vulnerable phases of the injured brain may abolish the neuroprotective effects of TH through ICP increase, excitotoxicity, increased metabolic demand and derangement of cerebrovascular reactivity [42,51-53]. A report of four patients treated with TH after CA observed an increase in LPR in all patients during rewarming indicating brain ischemia [28]. Slow and controlled rewarming after moderate hypothermia may prevent ICP increase and glutamate release and stabilize infarct volume [53]. Close monitoring of cerebral metabolism, ICP, CBF and brain tissue oxygenation can help to define the optimal rewarming rate to avoid increases in ICP (recommended rate of 0.1degreeC) and to early detect an imbalance in energy supply and demand. Conclusion: In the clinical setting there is still need to further explore the best induction and maintenance method, optimal duration and targeted temperature of therapeutic hypothermia. Due to the complexity of pathophysiologic mechanisms during hypothermia and rewarming, combining different advanced monitoring techniques seems mandatory. Multimodal neuromonitoring guidance may then help to define therapeutic targets and to establish clinical protocols to maximize the benefits of this emerging therapeutic modality.